This is to inform that due to some circumstances beyond the organizer control, “2nd Edition of International Conference on Gastroenterology” (Gastro 2024) during October 21-23, 2024 at Baltimore, MD, USA has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at gastroenterology@magnusconference.com or call + 1 (702) 988-2320.
Gastrointestinal (GI) drugs are medications used to treat conditions related to the digestive system. These drugs work to reduce inflammation, control acid production, and reduce symptoms such as abdominal pain, cramping, and diarrhea. The approval and regulation of GI drugs is a complex process that involves multiple government agencies. In the United States, the Food and Drug Administration (FDA) is responsible for evaluating new drugs for safety and efficacy before they are approved for use. After the FDA reviews a drug and finds it to be safe and effective for its intended use, the agency will issue an approval for its marketing. This approval includes a Drug Facts Label which contains important information about the drug including its side effects and warnings. In addition to the FDA, the Centers for Medicare and Medicaid Services (CMS) also has an important role in the approval process for GI drugs. CMS evaluates the cost effectiveness of drugs that are approved by the FDA. This means that the agency will consider the drug’s cost versus its benefit when determining whether to approve its use. CMS may also establish reimbursement policies that affect the cost of the drug and its availability to patients. In order to ensure that GI drugs are used safely and appropriately, the FDA also has regulations in place that govern the manufacturing, labeling, advertising, and distribution of these drugs. The agency also inspects drug manufacturing facilities to make sure that they are in compliance with these regulations. Finally, the FDA also works with healthcare providers to ensure that GI drugs are prescribed and used appropriately. The agency provides information to healthcare professionals about the safe and effective use of these medications and monitors the use of these drugs to ensure that they are being used properly. By regulating the approval and use of GI drugs, the FDA and CMS help ensure that these medications are safe and effective for their intended use. This helps to ensure that patients receive the best possible care when it comes to treating their gastrointestinal conditions.
Title : Novel exosomal biomarkers for MASH
Aleksandra Leszczynska, University of California San Diego, United States
Title : Validation of GLAS (GP73+LG2m+Age+Sex) and ASAP (Age+Sex+AFP+PIVKA-II) algorithms for the management of liver fibrosis, cirrhosis and cancer
Philip M Hemken, Abbott Diagnostics Division R&D, United States
Title : Reverse multiple myeloma: First hepatic amyloidosis then multiple myeloma
Milaris M Sanchez Cordero, Mayaguez Medical Center, Puerto Rico
Title : Autophagy promotes the survival of adipose mesenchymal stem/stromal cells and enhances their therapeutic effects in cisplatin-induced liver injury via modulating TGF-1/Smad and PI3K/AKT signaling pathways
Eman Mohamad EL Nashar, King Khalid University, Saudi Arabia
Title : Epigastric Impedance measures gastric malfunction non-invasively. Time to revive it
John Andrew Sutton, Gastria Ltd, United Kingdom
Title : Digesting the connection: Exploring the psychological impact of gastroenterology issues on mental and emotional well being
Tracy E Hill, MGS Products LLC, United States